The impact of thyroid function and TPOAb in the first trimester on pregnancy outcomes: a retrospective study in Peking.
The impact of mild TSH elevation (2.5-4.08 mIU/L) on pregnancy outcomes is unclear. The treatment strategy for mild TSH elevation is dependent on TPOAb status according to the guidelines. To assess the effects of mild thyroid dysfunction combined with TPOAb status in the 1st trimester on pregnancy outcomes and the impact of L-T4 treatment on pregnancy outcomes. The study retrospectively evaluated 3562 pregnant women. A total of 3296 untreated women were divided into four subgroups: Group A: 4.08<TSH<10 mIU/L, TPOAb+/-; Group B: 2.5<TSH≤4.08 mIU/L, TPOAb+; Group C: 2.5<TSH≤4.08 mIU/L, TPOAb-; and Group D: 0.23≤TSH≤2.5 mIU/L, TPOAb+/-. The other 266 women with L-T4 treatment were divided into TSH 4.08-10 mIU/L and 2.5-4.08 mIU/L subgroups. The study was conducted at Peking University First Hospital in China. A total of 3562 pregnant women were evaluated. There was no intervention. The incidence of pregnancy outcomes in the untreated subgroups (Groups A-D) and treated subgroups were measured. Miscarriage and maternal composite outcome risks were 3.53 (1.85-6.75) and 2.19 (1.26-3.81) times greater in Group A; 1.58 (1.17-2.13) and 1.27 (1.04-1.54) times greater in Group C than in Group D. L-T4 improved the miscarriage risk in the TSH 4.08-10 and 2.5-4.08 mIU/L groups but doubled the risk of gestational diabetes mellitus in the TSH 2.5-4.08 mIU/L treated group compared with the untreated group. TSH 2.5-4.08 mIU/L combined with TPOAb (-) during early pregnancy was associated with miscarriages and maternal composite outcomes. The advantages and disadvantages of L-T4 administration in TSH 2.5-4.08 mIU/L pregnant women remain uncertain.